Ra Capital Management, L.P. Sells 484,104 Shares of Vor Biopharma (NASDAQ:VOR) Stock

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 484,104 shares of Vor Biopharma stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $16.48, for a total value of $7,978,033.92. Following the completion of the transaction, the director owned 4,071,637 shares of the company’s stock, valued at approximately $67,100,577.76. This trade represents a 10.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, April 10th, Ra Capital Management, L.P. sold 828 shares of Vor Biopharma stock. The shares were sold at an average price of $15.75, for a total value of $13,041.00.
• On Thursday, April 9th, Ra Capital Management, L.P. sold 135,201 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total value of $2,242,984.59.
• On Monday, April 6th, Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total value of $9,775,773.63.
• On Thursday, April 2nd, Ra Capital Management, L.P. sold 260,000 shares of Vor Biopharma stock. The shares were sold at an average price of $18.23, for a total value of $4,739,800.00.

Vor Biopharma Stock Performance

Shares of NASDAQ VOR opened at $15.47 on Friday. The stock has a market cap of $755.71 million, a PE ratio of -0.04 and a beta of 1.92. Vor Biopharma Inc. has a fifty-two week low of $2.62 and a fifty-two week high of $65.80. The stock has a fifty day moving average of $14.41 and a 200-day moving average of $17.06.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Wells Fargo & Company began coverage on Vor Biopharma in a report on Thursday, March 19th. They set an “overweight” rating and a $30.00 price objective for the company. Wedbush raised their target price on shares of Vor Biopharma to $15.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Citigroup assumed coverage on shares of Vor Biopharma in a research report on Friday, January 9th. They set a “buy” rating and a $50.00 target price for the company. Wall Street Zen raised shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a research note on Saturday, April 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $50.67.

Hedge Funds Weigh In On Vor Biopharma

Several institutional investors have recently modified their holdings of the company. RA Capital Management L.P. raised its holdings in shares of Vor Biopharma by 172.7% during the 4th quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock valued at $70,697,000 after buying an additional 3,422,697 shares in the last quarter. Fcpm Iii Services B.V. raised its holdings in shares of Vor Biopharma by 852.8% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock valued at $47,315,000 after buying an additional 3,237,714 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new position in shares of Vor Biopharma during the 4th quarter valued at about $33,275,000. Paradigm Biocapital Advisors LP purchased a new position in shares of Vor Biopharma during the 4th quarter valued at about $22,890,000. Finally, NEXTBio Capital Management LP purchased a new position in shares of Vor Biopharma during the 4th quarter valued at about $13,080,000. 97.29% of the stock is currently owned by institutional investors.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).